Innovent Biologics
Founded in 2011 and listed in Hong Kong, Innovent Biologics develops, manufactures, and commercializes innovative treatments for oncology, autoimmune, metabolic, ophthalmic, and other major diseases, with multiple approved products. Its intensive R&D and multi-entity operations create demanding expense-allocation and cross-region tax requirements. It partnered with LoLR.AI and adopted the Group Tax Risk Management Appliance for unified tax-data collection and risk identification, supporting digital compliance management.